Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Stone

Showing results (531-540 of 544) with videos related to

Pageof 55
Sort By:
The New England Journal of Medicine|March 28, 2003
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndromeJan Cools, Daniel J DeAngelo, Jason Gotlib, et al.
Blood|August 18, 2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinibXin Victoria Wang, Curtis A Hanson, Renee C Tschumper, et al.
The New England Journal of Medicine|March 1, 2002
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemiaHagop Kantarjian, Charles Sawyers, Andreas Hochhaus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2024
Menin Inhibition With Revumenib for <i>KMT2A</i>-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, et al.
Nature Chemical Biology|October 3, 2017
Inhibition of USP10 induces degradation of oncogenic FLT3Ellen L Weisberg, Nathan J Schauer, Jing Yang, et al.
Blood Advances|April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplicationsHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
JCI Insight|February 23, 2026
Characterization of the clonal hierarchy and immunophenotype of PTPN11 mutations in acute myeloid leukemiaSydney Fobare, Chia Sharpe, Kate Quinn, et al.
Blood|January 29, 2011
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseMark Levis, Farhad Ravandi, Eunice S Wang, et al.
Applied Optics|June 17, 2006
Wide-field Fizeau imaging telescope: experimental resultsR L Kendrick, Jean-Noel Aubrun, Ray Bell, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
Pageof 55

Showing results (531-540 of 544) with videos related to

Sort By:
Pageof 55
The New England Journal of Medicine|March 28, 2003
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndromeJan Cools, Daniel J DeAngelo, Jason Gotlib, et al.
Blood|August 18, 2021
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinibXin Victoria Wang, Curtis A Hanson, Renee C Tschumper, et al.
The New England Journal of Medicine|March 1, 2002
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemiaHagop Kantarjian, Charles Sawyers, Andreas Hochhaus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2024
Menin Inhibition With Revumenib for <i>KMT2A</i>-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, et al.
Nature Chemical Biology|October 3, 2017
Inhibition of USP10 induces degradation of oncogenic FLT3Ellen L Weisberg, Nathan J Schauer, Jing Yang, et al.
Blood Advances|April 29, 2022
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplicationsHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
JCI Insight|February 23, 2026
Characterization of the clonal hierarchy and immunophenotype of PTPN11 mutations in acute myeloid leukemiaSydney Fobare, Chia Sharpe, Kate Quinn, et al.
Blood|January 29, 2011
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseMark Levis, Farhad Ravandi, Eunice S Wang, et al.
Applied Optics|June 17, 2006
Wide-field Fizeau imaging telescope: experimental resultsR L Kendrick, Jean-Noel Aubrun, Ray Bell, et al.
Leukemia|June 26, 2021
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasmsDavid P Steensma, Martin Wermke, Virginia M Klimek, et al.
Pageof 55